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Abstract
Selexipag is an oral prostacyclin receptor agonist; it was recently approved for use in adults with pulmonary arterial hypertension.
The safety and efficacy of selexipag has not yet been determined in the pediatric population. We describe short-term hemodynamic
and clinical data with selexipag therapy in four pediatric patients with pulmonary hypertension. We reviewed clinical, echocardio-
graphic, and hemodynamic data. One patient was transitioned from subcutaneous treprostinil to selexipag, and in three patients,
selexipag was added as a third agent. Drug dosing was attained empirically based on patient body size. A follow-up catheterization
was performed 12–18 months after initiation of selexipag therapy. All four patients tolerated selexipag well, without significant side
effects. One patient transitioned successfully from subcutaneous treprostinil to selexipag. None of the four patients had clinical
deterioration. In three patients who were able to perform a 6-minute walk test, pre and post selexipag distances were 350 and 400,
409 and 390, and 300 and 360 m, respectively. Echocardiograms showed no significant changes. Catheterization showed a variable
change in pulmonary vascular resistance (small decrease in three patients and increase in one patient). Brain natriuretic peptide
levels before and after selexipag in the four patients were 38 and 49, 33 and 54, 29 and 25, and 12 and 14 pg/mL, respectively.
Selexipag use for 16–28 months was safe in four pediatric patients; none of them had clinical deterioration. Larger number of
patients and longer follow-up intervals are necessary before further recommendations can be made.
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Introduction
Abnormal vascular smooth muscle cell contractility, pro-
liferation, and migration are important processes in the
development of pulmonary arterial hypertension (PAH).
Three molecular pathways have been the target of
PAH-specific medications, including nitric oxide—cyclic
guanosine monophosphate—phosphodiesterase, endothelin
receptors, and prostacyclin receptors. The prostacyclin
receptor (IP) is a membrane receptor coupled to a Gs type
protein, which leads to an increase in cAMP, resulting in
vasodilatory and anti-aggregatory effects. IP is also coupled
to Gi and Gq proteins, which causes a reduction in vascular
smooth muscle cell contraction, proliferation, and migra-
tion. Despite a reduction in IP receptor levels in end-stage
PAH, the antiproliferative effects of IP receptor agonists
appear to be preserved, with concurrent activation of both
the EP4 receptor and the PPARy pathway. Data suggest
that both IP receptor-dependent and -independent effects
are responsible for the antiproliferative effects of prostaglan-
din analogs.1–4
Selexipag, a selective IP receptor agonist, was approved
in December 2015 by the Food and Drug Administration
for the treatment of PAH World Health Organization
(WHO) Group 1 patients with functional class II or III to
delay the disease progression and reduce the risk of
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hospitalization. Selexipag has a similar mechanism of action
as prostacyclin (PGI2); however, selexipag is a nonprosta-
noid IP receptor agonist. Selexipag works as a pro-drug.
Its active metabolite (ACT-333679) has a 130-fold higher
selectivity for the IP receptor than other prostanoid recep-
tors. This high selectivity is probably responsible for the low
side effect profile of selexipag compared with the PGI2 ana-
logs. Moreover, it appears that selexipag does not cause IP
receptor desensitization and internalization, which avoids
the tachyphylaxis observed with PGI2 analogs.5,6
There are few published reports on the use of selexipag in
the pediatric population.7,8 We describe preliminary and
short-term hemodynamic (12–18 months) and clinical (16–
28 months) data with selexipag use in four pediatric
patients, one a former premature infant with chronic lung
disease and three with idiopathic PAH.
Case 1
A former 24-week premature infant with a birth weight of
589 g, chronic lung disease, pulmonary hypertension (group
3 PH), and a patent foramen ovale (PFO), underwent a
gastrostomy tube and ventriculo-peritoneal shunt placement
and revision. He was started on sildenafil. His first cardiac
catheterization at 5 months of age (Table 1) revealed supra-
systemic pulmonary arterial pressure with a pulmonary vas-
cular resistance indexed (PVRi) of 23.8 Wood units (WU).
He was started on subcutaneous treprostinil. A second cath-
eterization at 17 months of age revealed pulmonary arterial
pressure at g of systemic level with a PVRi of 9.4 WU. At
the request of the parents, the treprostinil was discontinued.
Bosentan was started. A third catheterization, at 2 years and
9 months of age, showed suprasystemic pulmonary arterial
pressure with a PVRi of 15.2 WU. Subsequent to the pro-
cedure, it was recommended to the parents to resume tre-
prostinil, but they remained strongly opposed. His WHO
functional class was II. Selexipag was started at 200mcg
(tablet dissolved in water) twice a day, with an increase
2 weeks later to 400mcg twice a day, and 2 weeks later to
600mcg twice a day. The parents reported no side effects.
At 3.5 years of age, his liver enzymes were elevated, and
he was therefore switched from bosentan to macitentan.
Sixteen months after starting selexipag, his weight was
13.4 kg and he was on nightly oxygen, sildenafil 10mg
three times a day, selexipag 600mcg twice a day, and maci-
tentan 3mg daily. A cardiac catheterization showed systemic
level pulmonary arterial pressure with a PVRi of 13.8 WU.
Twelve months later, he continued to do well clinically with-
out adverse effects from the medications. His brain natriuretic
peptide (BNP) level was 49pg/mL, compared with a BNP
level of 38pg/mL prior to starting selexipag. His echocardio-
gram was unchanged showing good left ventricular (LV)
function, moderate right ventricular dilatation with good
function, moderate flattening of the interventricular septum
in systole and trace tricuspid regurgitation.
Case 2
A girl presented at 11 years of age to the emergency depart-
ment with dyspnea, saturations in 70 s and 80 s, a murmur
and cardiomegaly on a chest x-ray. An echocardiogram
showed severe right-sided cardiac enlargement, moderate
tricuspid regurgitation with a peak velocity of 5m/s, mild
to moderate pulmonary regurgitation with a peak velocity
of 3.2m/s, a stretched PFO with right-to-left flow and good
LV function. At cardiac catheterization, she developed














5 months Baseline 85/44 (64) 59/38 (45) 23.8 0.77 Sildenafil
NO/O2 60/30 (45) 63/41 (52) 16.8 0.81 Start treprostinil
1 year 38
1 year, 5 months Baseline 62/15 (38) 80/39 (55) 9.4 0.64
NO/O2 53/12 (31) 80/42 (54) 7.7 0.47 End treprostinil
Start bosentan
2 years 9 months Baseline 84/26 (53) 72/43 (52) 15.2 1.0
NO/O2 83/23 (52) 74/43 (56) 12.6 0.85 Start selexipag
3 years 7 months End bosentan
Start macitentan
4 years 1 month Baseline 78/23 (49) 79/47 (60) 13.8 0.82 Selexipag¼ 16 months
NO/O2 69/17 (40) 78/45 (59) 10.3 0.64
4 years 11 months 49
AOp: aortic pressure; Baseline: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O2: oxygen; PAp pulmonary arterial pressure;
PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units.
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significant desaturation and hypotension in room air, so
baseline hemodynamics could not be obtained. On oxygen
and nitric oxide, she had systemic level pulmonary arterial
pressure (Table 2). A diagnosis of severe idiopathic PAH
(group 1 PH, WHO functional class II–III) was made.
She was started on sildenafil, furosemide, and subcutaneous
treprostinil. The patient underwent a second cardiac
catheterization a year later, which revealed suprasystemic
pulmonary arterial pressure with a PVRi of 24.3 WU.
Vasodilator testing with oxygen and nitric oxide resulted
in subsystemic pulmonary arterial pressure, with a PVRi
of 13 WU.
She was started on ambrisentan. Four months later, the
patient was suicidal and requested discontinuing treprostinil
(which was at a dose of 40 ng/kg/min). She was transitioned
to selexipag over a 4-week period, starting with a dose of
200mcg twice a day, increasing weekly until she reached
1000mcg twice a day. Simultaneously, the subcutaneous
treprostinil was weaned by 25% a week. The patient
reported significant improvement in energy level and exer-
cise tolerance in the ensuing weeks. Eighteen months later,
she weighed 58 kg and was on nightly oxygen, sildenafil
20mg three times a day, selexipag 1000mg twice a day,
and ambrisentan 10mg daily. At cardiac catheterization,
the pulmonary arterial pressure was slightly suprasystemic,
with a PVRi of 22.5 WU. Oxygen and nitric oxide adminis-
tration resulted in subsystemic pulmonary arterial pressure;
the PVRi decreased to 14.8 WU. Six months later, the
patient was doing well clinically with good exercise tolerance
and no symptoms. She carried her backpack at school with-
out difficulties. Her BNP level was 54 pg/mL compared with
a BNP level of 33 pg/mL prior to starting selexipag. Her
6-minute walk test (6-MWT) distance 2 years after starting
selexipag was 400m compared with 350m before starting
selexipag.
Case 3
A 2 years and 3 months old girl presented to the emergency
department after a syncopal episode with running. An echo-
cardiogram showed a dilated right heart, elevated tricuspid
regurgitation velocities, and good LV function. A cardiac
catheterization showed slightly suprasystemic pulmonary
arterial pressure with a PVRi of 15.6 WU (Table 3). A diag-
nosis of idiopathic PAH (group 1 PH, WHO functional class
II–III) was made and she was started on oxygen at night and
sildenafil. Seven months later, she had another syncopal epi-
sode with running vigorously and was started on bosentan.
A repeat cardiac catheterization at 4 years and 8 months of
age showed pulmonary pressures at about 80% of systemic
level with a PVRi of 10 WU.
Six months later, she was switched from bosentan to
ambrisentan. A cardiac catheterization at 6.5 years showed
pulmonary pressures at 72% of systemic level with a PVRi
of 9.3 WU. A repeat cardiac catheterization at 8.5 years of
age showed slightly subsystemic pulmonary arterial pres-
sure, with a PVRi of 11.5 WU. She was started on selexipag,
increasing the dose up to 600mcg twice a day over 2 weeks.
Due to dizziness and decreased activity level, unclear if
related to the new medication, the dose was transiently
decreased to 400mcg twice a day, and a few weeks later
increased back to 600mcg twice a day. Twelve months
after starting selexipag, she weighed 29 kg and was on
nightly oxygen, sildenafil 20mg three times a day, ambrisen-
tan 5mg a day, and selexipag 800mcg twice a day. A cath-
eterization showed subsystemic pulmonary arterial pressure
with a PVRi of 15.5 WU. Her BNP level was 25 pg/mL
compared with 29 pg/mL prior to starting selexipag. Her
6-minute walk distance was 390m compared with 409m
prior to starting selexipag. Four months later, the patient
was doing well clinically, without significant limitations.


















11 years 10 months Baseline N/A N/A N/A N/A
NO/O2 71/40 (53) 72/53 (63) 15.4 1.42 Start sildenafil
and treprostinil
12 years 10 months Baseline 94/51 (68) 80/51 (64) 24.3 1.2 350
NO/O2 81/31 (55) 90/48 (64) 13.0 0.8 Start ambrisentan
13 years 1 month 33
13 years 2 months End treprostinil
Start selexipag
13 years 10 months 400
14 years 8 months Baseline 89/48 (64) 79/49 (62) 22.5 1.1 Selexipag¼ 18 months
NO/O2 82/37 (56) 90/54 (52) 14.8 0.71
15 years 1 month 400 54
AOp: aortic pressure; Base: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O2: oxygen; PAp: pulmonary arterial pressure;
PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units; 6-MWT: 6-minute walk test.
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Case 4
A 14-months-old-girl presented with syncopal episodes.
An implantable loop recorder documented asystole of
4.5 s. A computed tomography angiogram showed dilation
of right-sided cardiac chambers and the pulmonary arteries.
A cardiac catheterization showed subsystemic pulmonary
arterial pressure with a PVRi of 10.7 WU (Table 4).
She had a PFO versus small atrial septal defect with
left-to-right flow. A diagnosis of idiopathic PAH (group 1
PH) was made, and treatment with sildenafil was started.
A cardiac catheterization at 2.5 years of age showed supra-
systemic pulmonary arterial pressure, with a PVRi of
14.5 WU. Vasodilator testing with nitric oxide and oxygen


















2 years 3 months Baseline 83/54 (67) 82/49 (65) 15.6 0.97
NO/O2 82/43 (61) 86/50 (69) 11.7 0.79 Start sildenafil
2 years 10 months Start bosentan
4 years 8 months Baseline 72/36 (52) 90/54 (71) 10.0 0.66
NO/O2 65/25 (43) 88/52 (69) 8.4 0.53
5 years 3 months End bosentan
Start ambrisentan
6 years 7 months Baseline 70/32 (51) 99/59 (68) 9.3 0.66
NO/O2 67/28 (46) 84/52 (73) 7.4 0.52
7 years 2 months 29
8 years 7 months Baseline 83/41 (60) 94/60 (75) 11.5 0.71 409
NO/O2 75/33 (52) 91/51 (72) 11.2 0.60 Start selexipag
9 years 9 months Baseline 75/37 (55) 83/53 (64) 15.5 0.79 Selexipag¼ 12 months 390 25
NO/O2 69/28 (46) 86/53 (69) 14.4 0.59
AOp: aortic pressure; Base: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O2: oxygen; PAp: pulmonary arterial pressure;
PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units; 6-MWT: 6-minute walk test.


















1 year 2 months Baseline 61/25 (42) 87/62 (73) 10.7 0.58
O2 54/17 (35) 82/57 (68) 6.5 0.29 Start sildenafil
2 years 5 months Baseline 102/42 (70) 74/46 (60) 14.5 1.16
NO/O2 80/29 (50) 90/58 (69) 9.3 0.65 Start bosentan
9 years 5 months Baseline 72/18 (42) 87/57 (72) 9.4 0.43
NO/O2 60/13 (34) 85/53 (68) 7.2 0.32
12 years 5 months Baseline 74/22 (48) 91/55 (73) 11.2 0.59
NO/O2 70/20 (40) 100/55 (75) 8.3 0.43
14 years 2 months 300 12
14 years 4 months Baseline 82/42 (62) 77/40 (64) 16.5 1.0
NO/O2 77/32 (55) 74/45 (52) 13.4 1.1 Start selexipag
15 years 7 months 360 14
15 years 8 months Baseline 80/41 (60) 79/57 (66) 13.9 0.86 Selexipag¼ 15 months
NO/O2 71/29 (49) 75/55 (65) 10.9 0.48
AOp: aortic pressure; Baseline: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O2: oxygen; PAp: pulmonary arterial pressure; PVRi:
pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units; 6-MWT: 6-minute walk test.
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resulted in subsystemic pulmonary arterial pressure. She was
started on bosentan.
She did well clinically for several years and underwent
catheterizations at 9.5 and 12.5 years of age revealing sub-
systemic pulmonary arterial pressures. A cardiac catheter-
ization performed at 14 years of age showed slightly
suprasystemic pulmonary arterial pressure with a PVRi of
16.5 WU. Her WHO functional class was II. Selexipag was
started at a dose of 200mcg twice a day, increasing the dose
weekly up to 1000mcg twice a day; however, she developed
diarrhea and headaches. The dose was decreased transiently
to 800mcg twice a day with resolution of side effects. Fifteen
months later, she weighed 67 kg and was on nightly oxygen,
sildenafil 20mg three times a day, bosentan 62.5mg twice a
day, and selexipag 1000mcg twice a day. A repeat catheter-
ization showed systemic level pulmonary arterial pressure
with a PVRi of 13.9 WU. After the administration of oxygen
and nitric oxide (20 ppm), the PVRi decreased to 10.9 WU.
Her BNP level was 14 pg/mL compared with 12 pg/mL prior
to starting selexipag. Her 6-minute walk distance was 360m
compared with 300m prior to starting selexipag. Four
months later, the patient was on selexipag at a dose of
1200mcg twice a day and was doing well clinically.
Discussion
Pediatric patients with PAH have traditionally been started
on one or two drugs, often a phosphodiesterase 5 inhibitor
and/or an endothelin receptor antagonist. Patients with
severe PAH or disease progression have been treated with
intravenous (IV) or subcutaneous prostacyclin analogs.
However, the difficulties with drug storage and delivery
and significant side effects and complications of the latter
have limited their use. The recent approval of an oral pros-
tacyclin receptor agonist, selexipag, has provided a newer
option to target this molecular pathway.
The GRIPHON study (NCT01106014)9 was a multicen-
ter, phase 3 study, in adult patients (selexipag: n¼ 574;
placebo: n¼ 582) with symptomatic (WHO class II and
III) PAH. Selexipag treatment duration was up to 4.2
years, with a median of 1.4 years. Selexipag reduced the
risk of time to first morbidity or mortality event by 40%
(p< 0.0001). The most frequent adverse effects of selexipag
in that and other studies were headache, myalgia, nausea,
pain in the jaw, arthralgia, skin irritation, diarrhea, pain in
the upper abdomen, and dizziness. Compared with PGI2
analogs, selexipag did not cause significant platelet dysfunc-
tion and was noted to cause stronger relaxation of the pul-
monary arteries. Bioavailability of selexipag after oral
administration was demonstrated to be approximately
50%.5,6,9–16
The first report of a pediatric patient treated with selex-
ipag was a 12-year-old girl with WHO functional class III,
right ventricular failure, recurrent syncope, dizziness, and
progressive fatigue.7 The patient had been previously treated
with bosentan and sildenafil with no improvement for
9 months. Selexipag was started and advanced to the
maximal dose of 1600mcg within 10 days. Six months
later, the patient had a decrease in PVR, right atrial pres-
sure, right ventricular end-diastolic pressure, right atrial and
right ventricular size, recovery of vasoreactivity and
improved cardiac index, 6-minute walking distance, func-
tional class, and body weight. Her only side effect was
mild to moderate nausea.
The largest reported series of selexipag use in the pediat-
ric age group is from the UCLA Mattel Children’s
Hospital,8 consisting of 10 patients (5 with idiopathic
PAH, 4 with congenital heart disease, and 1 with congenital
diaphragmatic hernia) with a mean age of 16.5 years. The
patients were on a phosphodiesterase 5 inhibitor and an
endothelin receptor antagonist; four were on IV treprostinil.
The four patients on IV treprostinil were successfully tran-
sitioned to oral selexipag. Selexipag was well tolerated, with
the most common side effects being headaches, loose stools,
and jaw pain. The maximum dose of 1600mcg was achieved
in all but one patient. The patients reported improved
energy, stamina, exercise tolerance, and decrease in oxygen
requirement. One patient became a candidate for cavopul-
monary anastomosis only after starting selexipag. Among 7
of the 10 patients who performed 6-MWT before and after
selexipag therapy, 3 had an increase and 4 had a decrease
in walk distance. Hemodynamic data were not obtained rou-
tinely before or after starting selexipag.
In a recent research letter, Koestenberger and
Hansmann17 briefly summarized their experience using
selexipag in nine patients ranging in age from 1.5 to
17 years and weight from 7 to 76 kg. Final doses were
400–1600mcg twice daily. In three of the nine patients, they
noted desaturation of more than 5%. When the dose was
decreased by 200mcg twice daily, the saturations improved,
presumably from less intrapulmonary shunting and subse-
quently lower drug metabolite levels. The most common side
effects they observed were nausea, vomiting, flushing, and
headache, all of which improved with anti-emetics.
Here, we report hemodynamic data, 6-MWT results, and
BNP levels before and 12–18 months after starting selexipag
in four pediatric PAH patients. In one patient, selexipag was
used as a substitute for subcutaneous treprostinil, in the
other three patients it was added as a third agent due to
hemodynamic deterioration. Each of the patients did well
clinically for 16–28 months after initiating selexipag. Two of
the three older patients reported improved exercise tolerance
and energy levels in the first few months after starting selex-
ipag; one reported no change. Two patients had transient
side effects, which resolved with temporary reduction of the
selexipag dose. The maximum dose utilized in each patient
was empiric, based on body weight. At cardiac catheteriza-
tion, PVRi did not change significantly (small decrease
in three patients and a small increase in one patient).
A 6-MWT could be performed in three of the patients; the
walk distance increased slightly in two and decreased
slightly in one. BNP levels were in the normal range
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(<100 pg/mL) in all four patients before and after selexipag
therapy; there was a small decrease in one and a slight
increase in three in BNP levels after the selexipag course.
We speculate that with added experience, selexipag could
be an alternative for patients who are on subcutaneous or IV
prostacyclin analogs and have significant adverse effects
with administration or tolerance. The other potential use
for selexipag could be as a third agent for WHO class II
or III patients who have worsening on a phosphodiesterase
inhibitor and an endothelin receptor antagonist. Whether
selexipag could be the second agent of initial double therapy
or the third agent of initial triple therapy for pediatric PH
patients remains to be determined by future studies.
There are limitations to our study. One is the small
number of patients, which precludes definitive conclusions
about the safety and effectiveness of selexipag in the pediat-
ric age group. In case 1, bosentan was replaced by maciten-
tan while on selexipag, and in case 2, ambrisentan was
started on the patient 4 months before selexipag. In these
two cases, it is not possible to know whether some of the
beneficial effect was from the endothelin receptor antagonist
and not selexipag. Also, the follow-up period of 16–28
months was relatively short. In addition, the final selexipag
dose attained in each patient may have been suboptimal.
A clinical phase 2 study, with about 55 PAH participants
aged 12–18 years, has the objective of determining more
optimal doses of Selexipag in children with PH. It started
enrolling in 2018 and has an estimated study completion
date of December 2025 [NCT03492177].18
In summary, our experience with selexipag for pediatric
PH adds to the limited published literature and suggests that
selexipag was well tolerated, with minimal side effects that
resolved with transient dose reduction. None of the patients
showed clinical signs of worsening. Hemodynamic data were
generally reassuring. Larger clinical experience and duration
of therapy will be necessary to make more definite recom-
mendations regarding the use of selexipag in pediatric
patients with PH.
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